Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, China
Copyright 2016, American College of Chest Physicians. All Rights Reserved.
SESSION TITLE: Lung Cancer IV
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: NSCLC is one of the severest malignancies dangerous for human’s health, whose morbidity and mortality are both highly increasing in all countries. Operative resection and postoperative adjuvant treatment are the best choice. The effect of adjuvant treatment depends on imaging tests. However, the patient was already in stage IV when recurrences or metastases were found by imaging tests. There are few successful treatment options for stage IV patients and the 5-year survival rate is less than 2%. Therefore, an early indicator on monitoring the therapeutic effects during adjuvant therapy for postoperative NSCLC patients is in need. Studies have showed that CTCs of peripheral blood is an important factor leading to disease progression and exacerbation, and could have diagnostic value in early stage of lung cancer. Therefore, we put forward hypothesis that EpCAM in CTCs in the peripheral blood can be an early indicator on monitoring the therapeutic effects during adjuvant therapy for postoperative NSCLC patients.
METHODS: The method of TaqMan probe RTFQ-PCR used in the earlier period experiment has been applied in the present study to detect the EpCAM in postoperative CTCs of peripheral blood for NSCLC patients, with the imaging diagnosis of recurrence and metastasis as the endpoint. The purpose of this study is to observe the difference of the EpCAM in postoperative CTCs of peripheral blood between recurrence group and non-recurrence group and initially explore the relationship between EpCAM in postoperative CTCs of peripheral blood and adjuvant therapy effects for postoperative NSCLC patients.
RESULTS: A total of 76 NSCLC patients were divided into recurrence group (n = 23) and non-recurrence group (n = 53). EpCAM in CTCs in the peripheral blood of both group patients before the fourth chemotherapy treatment are 5269.73±2356.39 copies/2ml and 3625.51±1790.39 copies/2ml, which is statistical significance (P = 0.008). The average monitoring time of EpCAM in postoperative CTCs of peripheral blood is 3.25 months. The average time of imaging diagnosis of recurrence and metastasis is 8.00±4.91 months. The result has statistical significance (P<0.0001).
CONCLUSIONS: EpCAM in CTCs in the peripheral blood is an good earlier indicator on monitoring the therapeutic effects during adjuvant therapy for postoperative NSCLC patients.
CLINICAL IMPLICATIONS: The monitoring of EpCAM in CTCs in the peripheral blood can be used as the basis for the formulation of adjuvant therapy for postoperative NSCLC patients.
DISCLOSURE: The following authors have nothing to disclose: Zhidong Liu, Dezhi Zhen, Yunsong Li, Chongyu Su, Kang Shi, Shijie Zhou, Shuku Liu, Yi Han, Daping Yu, Xiaoyun Song, Ning Xiao, Xiaoqing Cao
No Product/Research Disclosure Information
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.